Tag:
George Scangos
Latest Headlines
Latest Headlines
Biogen Idec bets it can succeed on a risky Phase III ALS gamble
Bloomberg biotech scribe Meg Tirrell has been plumbing Biogen Idec's late-stage drug for ALS and finds some good reasons to believe that they are on to something big.
Biogen chief brings in $11.3M in 2011 pay
Biogen Idec ( $BIIB ) CEO George Scangos (pictured) has restructured the company, streamlined R&D and benefited from drug development begun before his term began.
Biogen Idec races to FDA and EMA with a blockbuster app for BG-12
Biogen Idec has filed an NDA on BG-12 , another step in its blockbuster quest to gain an approval on its best near-term hope for a game-changing new treatment.
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix
Biogen Idec ( $BIIB ) has scooped up a biotech very close to home. The Weston, MA-based biotech power has bought nearby Stromedix , whose lead fibrosis drug STX-100 was licensed from Biogen. The deal
Biogen boosts R&D budget after research cutbacks
Biogen Idec ( $BIIB ) plans to spend about a quarter of its revenue this year on its research and development budget, after CEO George Scangos ( photo ) and his team cut multiple programs during 2010 and
Biogen CEO Scangos aims to patch weak points in pipeline
After two years of sweeping change at Biogen Idec ( $BIIB ), CEO George Scangos ( photo ) and his team have some work to do on plugging some of the holes in the company's early-stage pipeline, from which
Biogen CEO Scangos sees room for improvement in 2012
It's good to be the CEO of Biogen Idec ( $BIIB ). The stock has surged, there's a top late-stage candidate in the pipeline for MS, and everyone seems to like George Scangos ( photo ). In a wide-ranging
Exelixis strikes $251M portfolio pact with Merck
Exelixis ( $EXEL ) is banking a $12 million upfront from Merck ( $MRK ) under a licensing deal covering its PI3K-delta research work. With the biotech focused squarely on its controversial late-stage
Biogen Idec signs up with Samsung on $300 million biosimilars venture
Biogen Idec CEO George Scangos ( photo ) has made good on his vow to hammer out a major joint venture on biosimilars. The biotech has announced it is joining forces with South Korean conglomerate
Biogen partners with Portola in $553M autoimmune drug pact
Soon after taking the helm at Biogen Idec, George Scangos vowed to make the big biotech the "partner of choice" for other promising developers laboring in the same disease fields. This morning Biogen
